US › Healthcare

Avalyn Pharma Inc. Common Stock (AVLN)

US · Healthcare · Biotechnology

$30.73+7.82%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-26.9M
EPS
$-21.83
EPS estimate
$-0.81

EPS came in at -21.83 against a street estimate of -0.81 — a miss of 2595.1%.

Key statistics

Market cap
$1.26B
Forward P/E
0.0
P/B
11.71
Book value
$-214.41
EPS (TTM)
$-2.26
52-week high
$33.32
52-week low
$24.15
50-day MA
$28.68
200-day MA
$28.70

Analyst view

with an average price target of $59.00.

Shareholding

Institutions
61.84%

Largest institutional holders

FundStake
Andera Partners2.10%

Recent filings & reports

DocumentDate
Material agreement · Q2 20262026-07-01
Reg FD disclosure · Q2 20262026-06-17
Quarterly report · Q1 20262026-06-03
Results announced · Q2 20262026-06-03
Charter / bylaws change · Q2 20262026-05-01

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Avalyn Pharma Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.